Pharsight

Drugs that contain Oteseconazole

1. Vivjoa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8236962 MYCOVIA PHARMS Metalloenzyme inhibitor compounds
Apr, 2031

(7 years from now)

US9840492 MYCOVIA PHARMS Antifungal compounds and processes for making
Mar, 2036

(11 years from now)

US10414751 MYCOVIA PHARMS Antifungal compounds and processes for making
Mar, 2036

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8754227 MYCOVIA PHARMS Metalloenzyme inhibitor compounds
Apr, 2031

(7 years from now)

US11247981 MYCOVIA PHARMS Metalloenzyme inhibitor compounds
May, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 26, 2027
Generating Antibiotic Incentives Now(GAIN) Apr 26, 2032

NCE-1 date: 27 April, 2031

Market Authorisation Date: 26 April, 2022

Treatment: Vivjoa is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (rvvc) in females with a history of rvvc who are not of reproductive potential

Dosage: CAPSULE;ORAL

More Information on Dosage

VIVJOA family patents

Family Patents